IOBT / IO Biotech, Inc. - Net Long/Short Value

IO Biotech, Inc.
US ˙ NasdaqGS ˙ US4497781090

IOBT / IO Biotech, Inc. - Net Long/Short Value
Halaman ini menyediakan nilai bersih long/short untuk setiap kepemilikan institusional yang dilaporkan melalui pengajuan 13F atau NPORT. Untuk menghitung nilai bersih long/short, kami menambahkan nilai ekuitas ke nilai opsi beli (call option) dan mengurangi nilai opsi jual (put option). Dana yang melaporkan posisi short-borrowed akan melaporkan nilai ekuitas sebagai negatif. Posisi long bersih akan memiliki angka positif di kolom long/short bersih, dan posisi short bersih akan memiliki nilai negatif di kolom tersebut.
Pemilik Nilai Ekuitas
($1000)
Nilai Panggilan
($1000)
Masukkan Nilai
($1000)
Posisi Long/Short Bersih
($1000)
Cubist Systematic Strategies, LLC
Vivo Capital, LLC
SBI Securities Co., Ltd.
Two Sigma Securities, Llc
UBS Group AG
Marex Group plc
Marshall Wace, Llp
Renaissance Technologies Llc
Bank Of America Corp /de/
Citigroup Inc
GWM Advisors LLC
FNCMX - FIDELITY CONCORD STREET TRUST - Fidelity Nasdaq Composite Index Fund
Bridgeway Capital Management Inc
Novo Holdings A/S
Citadel Advisors Llc
Geode Capital Management, Llc
Dauntless Investment Group, LLC
Morgan Stanley
PFM Health Sciences, LP
Jane Street Group, Llc
XTX Topco Ltd
Pivotal bioVenture Partners Investment Advisor LLC
Soleus Capital Management, L.P.
BRSIX - BRIDGEWAY FUNDS INC - Ultra-Small Company Market Fund Class N
Raymond James Financial Inc
Landscape Capital Management, L.l.c.
Acadian Asset Management Llc
Sectoral Asset Management Inc
Fintel data has been cited in the following publications:
Daily Mail Fox Business Business Insider Wall Street Journal The Washington Post Bloomberg Financial Times Globe and Mail
NASDAQ.com Reuters The Guardian Associated Press FactCheck.org Snopes Politifact
Federal Register The Intercept Forbes Fortune Magazine TheStreet Time Magazine Canadian Broadcasting Corporation International Business Times
Cambridge University Press Investopedia MarketWatch NY Daily News Entrepreneur Newsweek Barron's El Economista